Published in Cancer Weekly, May 15th, 2006
According to "The Global Market for Adjunctive Therapies in Cancer," a new study from Kalorama Information, 2005 revenues for therapies addressing nausea, anemia, pain, and infections, among others, exceeded $17 billion. Indeed, from 2003 to 2005, the market grew by nearly 15%, primarily due to strong sales of biological response modifiers, and nausea, emesis, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.